Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
about
Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): health system experiences and prospectsCervical cancer and HPV vaccination: Knowledge and attitudes of adult women in Lusaka, ZambiaPerformance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009-2013.Using HPV vaccination for promotion of an adolescent package of care: opportunity and perspectives.Modeling the public health impact of malaria vaccines for developers and policymakersQuantifying clinical HPV4 dose inefficiencies in a safety net populationIntellectual property, technology transfer and manufacture of low-cost HPV vaccines in India.Aspects of prophylactic vaccination against cervical cancer and other human papillomavirus-related cancers in developing countries.Scaling up human papillomavirus vaccination: a conceptual framework of vaccine adherence.Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.Human papilloma virus vaccines: Current scenarioEstimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China.Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease.Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized studyHuman Papillomavirus Genotype Distribution in Invasive Cervical Cancer in PakistanHuman papillomavirus vaccines: new tools for accelerating cervical cancer prevention in developing countries.Primary prophylactic human papillomavirus vaccination programs: future perspective on global impact.Sexually transmitted infections and women's sexual and reproductive health.Cost effectiveness of human papilloma virus vaccination in low and middle income countries: a systematic review of literature.Cervical cancer screening in low- and middle-income countries.Cervical cytology and human papillomavirus among asymptomatic healthy volunteers in Vientiane, Lao PDR.Healthcare spending in the case of a HPV16/18 population-wide vaccination programme.Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region.Fathers' intentions to accept human papillomavirus vaccination for sons and daughters: exploratory findings from rural Honduras.Cost-effectiveness of 12- and 15-year-old girls' human papillomavirus 16/18 population-based vaccination programmes in Lithuania.Coverage, Timelines, and Determinants of Incomplete Immunization in Bangladesh
P2860
Q26864711-7A2D1AE2-1CB0-417F-B486-78D12289F6C6Q33819370-5FFB527C-F452-4E7C-98DD-6AE808047787Q33858092-B426EFE2-B138-4C39-B30D-583A7663A3D0Q34732730-B547CCA9-0D7E-4868-AFB1-5B93A0C662E5Q34787802-E18F720A-79BD-40E6-8D2D-1CFE2484D1CAQ35040145-C06F0040-D627-49FE-9E6E-1C5109DB7AF2Q35112350-C1BBE604-D36B-4EA1-AAF6-FF7B44E916B1Q35117498-5B6AF888-2D53-4AC6-97C6-C0B85874F60BQ35121855-D5A63D31-D23B-48F9-9B1F-FEA43316BD18Q35268615-16C5AE33-C879-473F-889F-3B77607C96C6Q35366075-B12A1E89-75D4-47B8-84D7-2D93D9501F26Q36183172-CA58090E-04E0-444B-82A6-483F7014496FQ36266671-89E2106C-9AC7-4E97-899B-C77AEBB69EA1Q36560944-B17764CA-F654-419B-A9D7-3CEDB9767652Q36977720-94F48D06-0C89-44EB-A121-2DF66DA8765EQ37208823-D0E34E92-6AB9-4480-9B2A-9D9AF8C25046Q37773300-97C1B32F-BBFB-434E-A518-EF79C15EB2ABQ37912228-F7EB7DB5-2A6E-486D-814F-CF6518FB2D8DQ39329108-112F4148-605B-4AB5-AB62-82B9DFFEE399Q45324144-6D546C55-FDC2-4EE1-9A1C-F6B6176409B0Q45952193-971AAFF5-09AD-401C-8510-E5B9CFD2DDEEQ47119314-0B8D556D-D512-4FB5-854A-05AB5C7D6874Q47356408-235B632E-9DBC-48CB-B36B-9CDBFD89304DQ47599014-F8D71BD4-DC89-44B5-908D-682D98EEFE0FQ48128191-E8977205-7AC5-4054-84C1-787613FB3E33Q51148505-50CD3F6C-25A5-433C-A491-D4717D3FAE1BQ57143387-C34E92EE-C50A-46A7-BBBC-A0A4AC743673
P2860
Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Benefits, cost requirements an ...... ountries: policy implications.
@en
type
label
Benefits, cost requirements an ...... ountries: policy implications.
@en
prefLabel
Benefits, cost requirements an ...... ountries: policy implications.
@en
P2860
P1476
Benefits, cost requirements an ...... ountries: policy implications.
@en
P2093
Meredith O'Shea
Sun-Young Kim
P2860
P356
10.1016/S0968-8080(08)32409-4
P577
2008-11-01T00:00:00Z